Newsfeeds - Spark Newswire

1 minute read

Why Sorrento Therapeutics’ Stock Is Trading Higher Today

Today, 10:28 PM

Sorrento Therapeutics (NASDAQ: SRNE) shares are trading higher after the company announced dosing of COVID-19 patients in its Phase 2 clinical trial for COVIDROPS, a neutralizing antibody against SARS-CoV-2.

SRNE

1 minute read

Sorrento Starts Patient Dosing In Mid-Stage COVID-19 Trial With Nasal Neutralizing Antibody

By Vandana Singh

Today, 10:28 PM

Sorrento Therapeutics Inc (NASDAQ: SRNE)

SRNE

3 minute read

FDA
News

Sorrento Announces Dosing Of COVID-19 Patients In Phase 2 Clinical Trial For COVIDROPS, A ‘Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta And Alpha Variants Of Concern’

By Benzinga Newsdesk

Today, 10:28 PM

Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , )))) today announced that COVID-19 patients have been dosed in its Phase 2 efficacy trial. Approximately 350 outpatients with COVID-19 who are

SRNE

1 minute read

FDA
News

Sorrento Therapeutics Reports Formation Of Sorrento Therapeutics Mexico For Commercialization Of COVI-STIX, Development Of Co.’s Portfolio Of COVID-19 Products In Mexico, Parts Of Latin America

By Benzinga Newsdesk

Today, 10:28 PM

Sorrento Therapeutics has established a Subsidiary Company in Mexico - Sorrento Therapeutics Mexico. Sorrento's Mexican importer of record has received an initial importation permit from Mexico Authority COFEPRIS

SRNE

5 minute read

FDA
News

Sorrento Therapeutics’ Scilex Holding Company Announces Complete Enrollment On Non-Opioid Injectable SP-102 Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management

By Benzinga Newsdesk

Today, 10:28 PM

Scilex Holding Company ("Scilex"), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )))), today announced complete enrollment of SP-102 (SEMDEXA™) Phase 3

SRNE

2 minute read

FDA
News

Sorrento Therapeutics Reports Partner Mabpharm Received Approval of Its New Drug Application for Its Infliximab Biobetter Antibody In China

By Benzinga Newsdesk

Today, 10:28 PM

China National Medical Product Administration (NMPA) has granted Mabpharm approval to market INFLIXIMAB biobetter in China. Sorrento holds commercialization rights outside of China and intends to

SRNE

1 minute read

Sorrento Therapeutics Shares Spike To Session High Following Tip Ranks Article ‘Sorrento: Big Potential for Pain Management Candidate’

By Benzinga Newsdesk

Today, 10:28 PM

https://twitter.com/TipRanks/status/1413202585226518533

SRNE

1 minute read

Trading Ideas

Sorrento Therapeutics Key Daily Technical Levels

By Benzinga Newsdesk

Today, 10:28 PM

YTD Support: $6.14 YTD Resistance: $17.25 Swing Support: $8.36 (Tested Today) Swing Resistance: $10.70-$11

SRNE

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 10:28 PM

Gainers

ADXS

1 minute read

Sorrento To Start Testing Non-Opioid Candidate In Osteoarthritis-Related Knee Pain

By Vandana Singh

Today, 10:28 PM

The FDA has signed off Sorrento Therapeutics Inc’s (NASDAQ:SRNE) Phase 2 study of Resiniferatoxin (RTX) for moderate-to-severe osteoarthritis of the knee…

SRNE